Health Trials

Clinical trials

4

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Recruiting

A Study Investigating Intravenous Human Normal Immune Globulin (IGIV) 10% KIg10 (QIVIGY) in Subjects With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

The current study is being conducted to assess the efficacy and safety of KIg10 (Intravenous Human Immune globulin 10%) at two different dosages as maintenance therapy for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) following 21 weeks of treatment.

Participants needed: 161
Trial details
Phase: Phase 3Age: 18+Biological sex: AllType: InterventionalSponsor: Kedrion S.p.A.Updated: Jul 1, 2026Locations: 3
Eligibility criteria

Male or female, aged ≥18 years. [+7]

Patients' incapable of giving informed consent. [+45]

Read more
Status: Recruiting

A Study Investigating Intravenous Human Normal Immunoglobulin 10% in Adults With Chronic Immune Thrombocytopenia (ITP)

The purpose of this study is to evaluate the efficacy and safety of KIg 10 (Intravenous Immunoglobulin 10%) in adult patients with chronic primary ITP

Participants needed: 40
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Kedrion S.p.A.Updated: Jun 16, 2026Locations: 27
Eligibility criteria

Male or female, 18-70 years of age. [+7]

Patients incapable of giving informed consent. [+34]

Read more
Status: Not yet recruiting

A Study Investigating Intravenous Human Normal Immune Globulin 10% in Adults With Stiff Person Syndrome

The purpose of this study is to evaluate the efficacy and safety of QIVIGY (Intravenous Human Normal Immune Globulin 10%) compared with placebo in adult participants with stiff person syndrome (SPS).

Participants needed: 38
Trial details
Phase: Phase 3Age: 18-70Biological sex: AllType: InterventionalSponsor: Kedrion S.p.A.Updated: Jun 10, 2026
Eligibility criteria

Male or female, 18-70 years of age. [+12]

Patients incapable of giving informed consent. [+27]

Read more
Status: Available

Sponsor Initiated Expanded Access Protocol, Intermediate-Size Patient Population

The purpose of this protocol is to provide compassionate use of Kedrion Human Plasminogen Ophthalmologic Drops to an expanded population of patients diagnosed with ligneous conjunctivitis associated with type I Plasminogen deficiency until product licensure, and/or until a new clinical trial is available and the patients in treatment under Expanded Access are eligible to participate in the new trial.

Trial details
Biological sex: AllType: Expanded AccessSponsor: Kedrion S.p.A.Updated: Oct 5, 2023
Eligibility criteria

Subjects diagnosed with LC associated with Type I plasminogen deficiency, confir... [+3]

Subjects with any condition which, in the opinion of the treating physician or s... [+2]

Read more